Figure 3.
Quantitative analysis of α6β2* and α4β2* receptor levels in ST and OT. A–C, αCtxMII (50 nm) inhibition of [125I]-epibatidine binding separates α6β2* and α4β2* subtypes in ST of WT, α6L9′S, α4KO, and α4KO/α6L9′S mice. Membrane preparations from ST of the indicated mice were incubated with [125I]epibatidine in the presence and absence of competing, unlabeled αCtxMII. Raw binding values (C) for MII-resistant (mainly α4β2*) and MII-sensitive (mainly α6β2*) receptors (A), as well as percentage of MII-sensitive receptors (B) are shown. D–F, α6β2* and α4β2* receptor analysis for OT was performed identical to ST (A–C). Data are expressed as mean ± SEM. The number of mice in each group was as follows: WT, n = 7; α6L9′S, n = 7; α4KO, n = 6; α4KO/α6L9′S, n = 5. All statistically significant comparisons are indicated. *p < 0.05, **p < 0.01, ***p < 0.001.